相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- ArriVent BioPharma expects topline data from the global pivotal FURVENT Phase 3 trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second half of 2026. - The company advanced ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, into Phase 1b dose optimization and plans first-patient dosing for ARR-002, a dual-targeting MUC16/NaPi2b ADC, in Q3 2026. - Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations and is also being studied in the ALPACCA Phase 3 trial for EGFR PACC-mutant NSCLC. - ArriVent reported $373.1 million in cash and investments as of June 30, 2026, expected to fund operations into 2028.
- ArriVent BioPharma has dosed the first patient in the global pivotal Phase 3 ALPACCA trial evaluating firmonertinib for first-line treatment of EGFR PACC mutant non-small cell lung cancer. - The randomized study compares firmonertinib 240 mg once daily against investigator's choice of osimertinib or afatinib, targeting an underserved population with limited treatment options. - PACC mutations represent approximately 12% of all EGFR mutations and affect an estimated 42,000 patients globally and 6,200 patients annually in the US. - The trial is designed to support potential accelerated and full regulatory approvals based on compelling prior data showing 16-month median progression-free survival and 68% overall response rate.
